Statin-Induced Myopathy Is Associated with Mitochondrial Complex III Inhibition.

[1]  M. Medina,et al.  GATM polymorphism associated with the risk for statin-induced myopathy does not replicate in case-control analysis of 715 dyslipidemic individuals. , 2015, Cell metabolism.

[2]  R. Rodenburg,et al.  SDHA mutations causing a multisystem mitochondrial disease: novel mutations and genetic overlap with hereditary tumors , 2014, European Journal of Human Genetics.

[3]  K. Reue,et al.  Lipin-1 regulates autophagy clearance and intersects with statin drug effects in skeletal muscle. , 2014, Cell Metabolism.

[4]  D. Barrett,et al.  Translational insight into statin-induced muscle toxicity: from cell culture to clinical studies. , 2014, Translational research : the journal of laboratory and clinical medicine.

[5]  D. Voora,et al.  Phenotype Standardization for Statin-Induced Myotoxicity , 2014, Clinical pharmacology and therapeutics.

[6]  W. Tong,et al.  Drug-induced rhabdomyolysis: from systems pharmacology analysis to biochemical flux. , 2014, Chemical research in toxicology.

[7]  F. Mastaglia,et al.  Statin myotoxicity: A review of genetic susceptibility factors , 2014, Neuromuscular Disorders.

[8]  B. Psaty,et al.  GATM gene variants and statin myopathy risk , 2014, Nature.

[9]  P. Thompson,et al.  Does reduced creatine synthesis protect against statin myopathy? , 2013, Cell metabolism.

[10]  Christopher D. Brown,et al.  A statin-dependent QTL for GATM expression is associated with statin-induced myopathy , 2013, Nature.

[11]  A. Åsberg,et al.  UGT1A1*28 is Associated with Decreased Systemic Exposure of Atorvastatin Lactone , 2013, Molecular Diagnosis & Therapy.

[12]  Lucía Pronsato,et al.  High passage numbers induce resistance to apoptosis in C2C12 muscle cells. , 2013, Biocell : official journal of the Sociedades Latinoamericanas de Microscopia Electronica ... et. al.

[13]  P. Thompson,et al.  Effect of Statins on Skeletal Muscle Function , 2012, Circulation.

[14]  J. DiNicolantonio.  CoQ10 and L-carnitine for statin myalgia? , 2012, Expert review of cardiovascular therapy.

[15]  Beatrice A. Golomb,et al.  A Survey of the FDA's AERS Database Regarding Muscle and Tendon Adverse Events Linked to the Statin Drug Class , 2012, PloS one.

[16]  Tina Ritschel,et al.  Pharmacophore Fingerprint-Based Approach to Binding Site Subpocket Similarity and Its Application to Bioisostere Replacement , 2012, J. Chem. Inf. Model..

[17]  P. Sirvent,et al.  Muscle mitochondrial metabolism and calcium signaling impairment in patients treated with statins. , 2012, Toxicology and applied pharmacology.

[18]  S. Krähenbühl,et al.  Susceptibility to simvastatin-induced toxicity is partly determined by mitochondrial respiration and phosphorylation state of Akt. , 2011, Biochimica et biophysica acta.

[19]  T. A. Jacobson,et al.  Statin-induced myopathy: a review and update , 2011, Expert opinion on drug safety.

[20]  C. Angelini,et al.  EFNS guidelines on the diagnostic approach to pauci‐ or asymptomatic hyperCKemia , 2010, European journal of neurology.

[21]  R. Rodenburg.  Biochemical diagnosis of mitochondrial disorders , 2010, Journal of Inherited Metabolic Disease.

[22]  S. Krähenbühl,et al.  Effect of simvastatin on cholesterol metabolism in C2C12 myotubes and HepG2 cells, and consequences for statin-induced myopathy. , 2010, Biochemical pharmacology.

[23]  E. Gnaiger.  Capacity of oxidative phosphorylation in human skeletal muscle: new perspectives of mitochondrial physiology. , 2009, The international journal of biochemistry & cell biology.

[24]  F. Daldal,et al.  The role of molecular modeling in the design of analogues of the fungicidal natural products crocacins A and D. , 2008, Bioorganic & medicinal chemistry.

[25]  R. Houtkooper,et al.  Mutations in LPIN1 cause recurrent acute myoglobinuria in childhood. , 2008, American journal of human genetics.

[26]  R. Collins,et al.  SLCO1B1 variants and statin-induced myopathy--a genomewide study. , 2008, The New England journal of medicine.

[27]  P. Sirvent,et al.  New insights into mechanisms of statin-associated myotoxicity. , 2008, Current opinion in pharmacology.

[28]  R. Margreiter,et al.  Analysis of mitochondrial function in situ in permeabilized muscle fibers, tissues and cells , 2008, Nature Protocols.

[29]  A. Åsberg,et al.  Statin induced myotoxicity: the lactone forms are more potent than the acid forms in human skeletal muscle cells in vitro. , 2008, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[30]  J. Smeitink,et al.  Life cell quantification of mitochondrial membrane potential at the single organelle level , 2008, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[31]  Michiaki Yamashita,et al.  The muscle-specific ubiquitin ligase atrogin-1/MAFbx mediates statin-induced muscle toxicity. , 2007, The Journal of clinical investigation.

[32]  J. Armitage,et al.  The safety of statins in clinical practice , 2007, The Lancet.

[33]  P. Thompson,et al.  The role of coenzyme Q10 in statin-associated myopathy: a systematic review. , 2007, Journal of the American College of Cardiology.

[34]  R. Rodenburg,et al.  Spectrophotometric assay for complex I of the respiratory chain in tissue samples and cultured fibroblasts. , 2007, Clinical chemistry.

[35]  Anne E Carpenter,et al.  CellProfiler: image analysis software for identifying and quantifying cell phenotypes , 2006, Genome Biology.

[36]  Zachary Simmons,et al.  Genetic risk factors associated with lipid‐lowering drug‐induced myopathies , 2006, Muscle & nerve.

[37]  R. Rodenburg,et al.  Measurement of the energy-generating capacity of human muscle mitochondria: diagnostic procedure and application to human pathology. , 2006, Clinical chemistry.

[38]  A. Arduini,et al.  Improvement of statin‐associated myotoxicity by L‐carnitine , 2004, Journal of thrombosis and haemostasis : JTH.

[39]  A. Sánchez Navarro,et al.  Clinical pharmacokinetics of statins. , 2003, Methods and findings in experimental and clinical pharmacology.

[40]  C. M. White.  A Review of the Pharmacologic and Pharmacokinetic Aspects of Rosuvastatin , 2002, Journal of clinical pharmacology.

[41]  B. Ma,et al.  Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[42]  Bertram Pitt,et al.  Withdrawal of cerivastatin from the world market , 2001, Current controlled trials in cardiovascular medicine.

[43]  J. Deisenhofer,et al.  Structural Mechanism for Statin Inhibition of HMG-CoA Reductase , 2001, Science.

[44]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..

[45]  F. Gabreëls,et al.  Clinical heterogeneity in respiratory chain complex III deficiency in childhood , 1997, Journal of the Neurological Sciences.

[46]  B. Trumpower,et al.  The protonmotive Q cycle in mitochondria and bacteria. , 1994, Critical reviews in biochemistry and molecular biology.

[47]  H. Schägger,et al.  Characterisation of binding of the methoxyacrylate inhibitors to mitochondrial cytochrome c reductase. , 1988, European journal of biochemistry.